Antisteroids block the action of steroid hormones. For this reason, antisteroids have been attractive clinical tools to suppress the effects of endogenous steroids both in a variety of disorders, including breast and uterine cancers, and in birth control. Much research has been devoted to finding pure antisteriods that would prevent any action of endogenous steriods. Unfortunately, antisteriod treatments are associated with many side effects, most of which result from the repression of the wide variety of normally expressed genes. For this reason, attention has recently shifted to selective receptor modulators (SRMs), which are antisteroids with partial agonist activity with some responsive genes. Those SRMs that cause the repression of the fewest genes, other than the genes that are targeted for inhibition, would be expected to have the fewest side effects and the widest clinical applications. Almost all existing antiprogestins suffer from two disadvantages. First, they block virtually all actions of progesterone receptors and display very little partial agonist activity. Second, most progestins are also potent antiglucocorticoids and suppress genes regulated by glucocorticoids, thus expanding the scope of undesirable side effects. Presently, the only antiprogestin reported to have significant amounts of partial agonist activity, and thus any prospect of being a selective progesterone receptor modulator (SPRM), is RTI 3021–020.

The NIH now announces that two derivatives of the potent glucocorticoid dexamethasone (Dex) show partial agonist activity under a variety of conditions and represent novel leads to new SPRMs. These derivatives are Dex-21-mesylate (Dex-Mes) and Dex-oxetanone (Dex-Ox). In direct comparisons with RTI 3021–020, Dex-Mes and Dex-Ox have consistently displayed more partial agonist activity even under conditions where RTI 3021–020 was inactive. Therefore, Dex-Mes, Dex-Ox, or other Dex derivatives, may be useful as partial progesterone agonists under a wider variety of conditions both in the laboratory and in the clinical setting, such as the treatment of endometriosis and leiomyomas of the uterus, to name a few. Furthermore, Dex-Mes and Dex-Ox also possess partial agonist activity with glucocorticoid receptors, thus reducing the side effects resulting from the repression of glucocorticoid-regulated genes.

Dated: January 24, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01–2809 Filed 2–1–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Fogarty International Center; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Fogarty International Center Advisory Board.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Fogarty International Center Advisory Board.

Date: February 6, 2001.

Open: 8:30 AM to 12:00 PM.

Agenda: Report of the Director and presentations on Disease Control Priorities Report of the Macroeconomic Commission on Health, and on FIC programs and plans.

Place: Lawton Chiles International House, 16 Center Drive, (Building 16), Bethesda, MD 20892.

Closed: 1:00 PM to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Lawton Chiles International House, 16 Center Drive, (Building 16), Bethesda, MD 20892.

Contact Person: Irene W. Edwards, Information Officer, Fogarty International Center, National Institutes Of Health, Building 31, Room B2C08, 31 Center Drive MSC 2220, Bethesda, MD 20892, 301–496–2075.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.106, Minority International Research Training Grant in the Biomedical and Behavioral Sciences; 93.154, Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome; 93.168, International Cooperative Biodiversity Groups Program; 93.934, Fogarty International Research Collaboration Award; 93.989, Senior International Fellowship Awards Program, National Institutes of Health, HHS)

Dated: January 26, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–2805 Filed 2–1–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended to disclosure information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Board of Scientific Advisors.

Date: March 5–6, 2001.

Open: March 5, 2001, 8:00 AM to 12:00 PM.

Agenda: Joint meeting of the NCI Board of Scientific Advisors and NCI Board of Scientific Counselors; Report of the Director, NCI; and Scientific Presentations.

Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6 Floor, Conference Room 10, Bethesda, MD 20892.

Open: March 5, 2001 12:00 PM to 5:00 PM.

Agenda: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentation; Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations.

Place: National Cancer Institute; 9000 Rockville Pike, Building 31, C Wing, 6 Floor, Conference Room 10, Bethesda, MD 20892.